AFCM
REGN icon

Applied Finance Capital Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Applied Finance Capital Management’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.55M Sell
13,713
-3,122
-19% -$2.13M 0.64% 55
2026
Q1 		$13M Sell
16,835
-2,246
-12% -$1.72M 0.98% 43
2025
Q4 		$14.7M Sell
19,081
-3,138
-14% -$2.13M 1.05% 40
2025
Q3 		$12.5M Sell
22,219
-764
-3% -$432K 0.89% 43
2025
Q2 		$12.1M Buy
22,983
+3,190
+16% +$1.78M 0.82% 47
2025
Q1 		$12.6M Sell
19,793
-8,524
-30% -$5.86M 0.92% 46
2024
Q4 		$20.2M Buy
28,317
+54
+0.2% +$45.3K 0.88% 51
2024
Q3 		$29.7M Sell
28,263
-1,890
-6% -$2.1M 1.27% 40
2024
Q2 		$31.7M Buy
30,153
+8,000
+36% +$7.76M 1.47% 31
2024
Q1 		$21.3M Sell
22,153
-132
-0.6% -$126K 1.5% 40
2023
Q4 		$19.6M Buy
22,285
+1,803
+9% +$1.48M 1.7% 32
2023
Q3 		$16.9M Buy
20,482
+1,738
+9% +$1.37M 1.83% 26
2023
Q2 		$13.5M Sell
18,744
-2,333
-11% -$1.8M 1.53% 38
2023
Q1 		$17.3M Buy
21,077
+222
+1% +$167K 2.15% 15
2022
Q4 		$15M Buy
+20,855
New +$15.4M 1.96% 21

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Applied Finance Capital Management's REGN Position: Q2 2026 in Review

Applied Finance Capital Management reduced its Regeneron Pharmaceuticals (REGN) stake by 19% in Q2 2026, selling an estimated $2.13M and leaving 13,713 shares worth $8.55M. The position accounts for 0.64% of the portfolio, ranked #55.

Applied Finance Capital Management first reported a position in REGN in Q4 2022 and has held it in 15 quarters since. The position peaked at $31.7M in Q2 2024. 1,333 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Applied Finance Capital Management held 13,713 shares of Regeneron Pharmaceuticals worth $8.55M as of Q2 2026.
  • Applied Finance Capital Management sold 3,122 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $2.13M.
  • Regeneron Pharmaceuticals made up 0.64% of Applied Finance Capital Management's portfolio in Q2 2026, its #55 holding.
  • Applied Finance Capital Management first reported a position in Regeneron Pharmaceuticals in Q4 2022 and has held it in 15 quarters since.
  • Applied Finance Capital Management's Regeneron Pharmaceuticals position peaked at $31.7M in Q2 2024.
  • 1,333 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Applied Finance Capital Management's 13F filing for Q2 2026, filed 28 Jul 2026.